Intellegens
Cambridge
About Intellegens
Intellegens applies machine learning to accelerate innovation for materials, chemicals, manufacturing, and beyond. Extract more value from real-world, sparse, noisy data. Win with optimised formulations, products, and processes. Save time and cost with up to 90% fewer experiments. We enable you to deploy advanced deep learning for maximum impact. Intellegens' Alchemite™ software, first developed at the University of Cambridge, trains deep neural networks from sparse, noisy data, where most machine learning approaches fail. Scientists, engineers, and analysts apply Alchemite™ through a simple web browser user interface, with powerful graphical analysis tools. Data science teams can integrate the Alchemite™ algorithm with their own tools, scripts, and workflows. This flexibility overcomes the challenges of deploying machine learning in real business and research environments. Successful applications included materials development, additive manufacturing, drug discovery, chemistry, manufacturing processes, plastics, and formulated products. Visit intellegens.ai for more information.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $2.0M
- Funding stage: Seed
- Last round: Grant (Aug 2023)
- Website: intellegens.com
- Phone: 07810303762
Industries & Categories
Artificial Intelligence (AI), Biotechnology, Machine Learning, Pharmaceutical, Software
Social Profiles
Canonical: https://fsome.com/organization/intellegens-65406 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.